An ortho friend asked me this interesting financial question and there is a simple answer.
This is a classic case study in why the "Top Line" (revenue) rarely tells the whole story. As of March 2026, SI-BONE (SIBN) and Treace Medical Concepts (TMCI) both hover around the $200M–$213M annual revenue mark, yet their valuations have diverged into two completely different worlds.
While SI-BONE has maintained a market cap in the $600M–$660M range, Treace has plummeted to a valuation of approximately $80M–$110M.
The Tale of Two Tickers (FY 2025/2026)
Metric
SI-BONE (SIBN)
Treace Medical (TMCI)
...
